Monte Rosa Therapeutics, Inc

GLUE · United States

Share price · GLUE

$9.07-5.96 (-39.65%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GLUE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Nov 2026-9.7%
  2. 31 Jul 2026-27.2%
  3. 14 Jul 2026+6.7%
  4. 23 Jun 2026+10.9%
  5. 12 Jun 2026+6.6%
  6. 2 Jun 2026-9.8%
  7. 12 May 2026-5.7%
  8. 21 Apr 2026+5.5%
  9. 7 Jan 2026+45.4%
  10. 16 Dec 2025+13.4%

Share of unusual movement by asset

For each asset, the share of GLUE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
MRT-2359
events and moves
5shown from 8 days
MRT-6160
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—58%
Sessions with no dated event—40%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
GSPT1Small molecule
Non-Small Cell Lung CancerBreast CancerProstate Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
VAV1Small molecule
Sjögren's Disease

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
MRT-2359Phase 1/2NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors …
Est. primary completion 2026-12 · NCT05546268 · CT.gov ↗
What to watch
2027 (1)
October 2027 (1)
MRT-2359Phase 2Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Est. primary completion 2027-10 · NCT07745361 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
MRT-6160Phase 2Moderate to Severe Psoriatic Arthritis
Est. primary completion 2028-12-13 · NCT07801495 · CT.gov ↗
What to watch
2029 (2)
February 2029 (1)
MRT-6160Phase 2Sjögren's Disease
Est. primary completion 2029-02-19 · NCT07737743 · CT.gov ↗
What to watch
December 2029 (1)
MRT-6160Phase 2Moderate to Severe Psoriatic Arthritis
Est. primary completion 2029-12-12 · NCT07923773 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$54M$45M$50M+ $533M short-term inv.—-$41M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$9.0M$48M$95M+ $531M short-term inv.$43M-$44M operating cash flowreport ↗
2026-Q1$4.2M$44M$165M+ $506M short-term inv.$45M-$37M operating cash flowreport ↗
2025-Q3$13M$37M$213M+ $183M short-term inv.$27M$100M operating cash flowreport ↗
2025-Q2$23M$31M$74M+ $221M short-term inv.$12M-$35M operating cash flowreport ↗
2025-Q1$85M$32M$83M—-$45M operating cash flowreport ↗
2024-Q3$9.2M$28M$130M$24M-$21M operating cash flowreport ↗
2024-Q2$4.7M$28M$114M$30M-$28M operating cash flowreport ↗
2024-Q1$1.1M$27M$105M$32M-$38M operating cash flowreport ↗
2023-Q3$0$28M$64M$35M-$25M operating cash flowreport ↗
2023-Q2$0$29M$52M$35M-$25M operating cash flowreport ↗
2023-Q1$0$27M$57M$32M-$23M operating cash flowreport ↗
2022-Q3—$21M$118M$27M-$21M operating cash flowreport ↗
2022-Q2—$21M$109M$26M-$21M operating cash flowreport ↗
2022-Q1—$18M$144M$24M-$27M operating cash flowreport ↗
2021-Q3—$15M$369M$20M-$18M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$124M$142M$135M+ $247M short-term inv.$9.7M-$23M operating cash flowreport ↗

Monte Rosa Therapeutics reported full-year 2025 collaboration revenue of $123.67M, up 63.5% YoY, with R&D spend of $141.5M, up 16.4% YoY. The company ended the period with cash and equivalents of $134.84M and reported a net loss of $38.63M for the year.

Business updates include positive interim Phase 1 data for NEK7-directed MRT-8102 showing CRP reductions in elevated cardiovascular-risk subjects, with an expanded GFORCE-1 proof-of-concept readout expected in H2 2026 and multiple Phase 2 studies planned across CVD-risk, gout flares, and hidradenitis suppurativa. MRT-2359 interim data showed a 100% PSA response rate in mCRPC patients with AR mutations, with a Phase 2 study in combination with apalutamide anticipated in Q3 2026. Novartis is expected to initiate multiple Phase 2 studies of VAV1-directed MRT-6160, and the company guided that its cash position, following a roughly $345M upsized financing, supports operations into 2029.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$76M$122M$229M$18M$42M operating cash flowreport ↗
2023-FY$0$111M$133M$34M-$44M operating cash flowreport ↗
2022-FY—$85M$60M$27M-$92M operating cash flowreport ↗
2021-FY—$57M$351M$18M-$59M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 37 sales ($4.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-05Bowen Matthew · Principal Accounting OfficerOpen-market sale13$10.56$137Form 4
2026-07-16Warmuth Markus · director, President & CEOOpen-market sale9,500$23.18$220KForm 4
2026-07-15Champoux Jennifer · Chief Operating OfficerOption exercise4,351$3.98$17KForm 4
2026-07-15Champoux Jennifer · Chief Operating OfficerOpen-market sale4,351$23.38$102KForm 4
2026-07-15Champoux Jennifer · Chief Operating OfficerOption exercise (derivative)4,351——Form 4
2026-07-06Townson Sharon · Chief Scientific OfficerOption exercise6,000$6.14$37KForm 4
2026-07-06Townson Sharon · Chief Scientific OfficerOpen-market sale5,600$23.25$130KForm 4
2026-07-06Townson Sharon · Chief Scientific OfficerOpen-market sale400$24.13$10KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 189 reporting institutions held 86.9M shares ($1.3B, 101.7% of shares outstanding).

#InstitutionSharesValue
1NEA Management Company, LLC7,692,298$126.5M
2BlackRock, Inc.5,637,684$92.7M
3TCG Crossover Management, LLC4,622,151$76.0M
4BVF INC/IL4,460,886$73.4M
5BAKER BROS. ADVISORS LP4,345,736$71.5M
6SUVRETTA CAPITAL MANAGEMENT, LLC4,226,809$69.5M
7Vestal Point Capital, LP3,603,465$59.3M
8STATE STREET CORP3,353,980$55.2M
9BRAIDWELL LP3,206,574$52.7M
10Versant Venture Management, LLC3,180,780$52.3M
11VANGUARD CAPITAL MANAGEMENT LLC3,100,245$51.0M
12AMERICAN CENTURY COMPANIES INC2,809,647$46.2M
13SILVERARC CAPITAL MANAGEMENT, LLC2,002,040$32.9M
14Aisling Capital Management LP1,555,664$25.6M
15GEODE CAPITAL MANAGEMENT, LLC1,540,812$25.4M